TNFRSF17 as a complementary biomarker to PD-L1 for predicting the response to immunotherapy in urothelial bladder cancer. Chen J, Li B, Gan Y, Li P, et al. PLoS One 2026;21:e0346131.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Chen J, Li B, Gan Y, Li P, et al. TNFRSF17 as a complementary biomarker to PD-L1 for predicting the response to immunotherapy in urothelial bladder cancer. PLoS One 2026;21:e0346131.
PMID: 41931481